Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
NicOx S.A.
ALCOXNicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. Nicox S.A. is developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France. Address: Sundesk Sophia Antipolis, Valbonne, France, 06410
Analytics
Objectif de Cours de WallStreet
0.92 EURRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés ALCOX
Analyse des dividendes ALCOX
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes ALCOX
Valorisation des titres ALCOX
financières ALCOX
Résultats | 2019 | Dynamique |